Blog

New handheld payments and ordering device combines full POS functionality, payment acceptance, and business management tools in one powerful, standalone solution for American entrepreneurs.

BOULDER, CO / ACCESS Newswire / November 20, 2025 / SumUp, the financial technology company dedicated to empowering small merchants, today announces the U.S. launch of its new SumUp Terminal, an all-in-one, handheld device that brings together full Point of Sale (POS) functionality, fast payment acceptance, and essential business management tools in a sleek, mobile device.

Built for day-to-day realities of running a small business, the Terminal removes the need for bulky setups or a connected smartphone. It operates independently with Wi-Fi or its built-in cellular connection (eSIM card included), a key differentiator that ensures reliable, on-the-go functionality wherever business happens.

The SumUp Terminal runs the powerful SumUp SuperApp, giving entrepreneurs access to everything they need to run their business:

• Accept Payments Anywhere: Process tap, dip, or swipe transactions with affordable and transparent pricing at 2.6% + 10¢ for all card-present payments. The device features long-lasting battery life for full-day operation and reliable connectivity with built-in 4G and Wi-Fi backup.

• Streamline Operations: The intuitive touchscreen and larger display enable complex features like table management, easy item catalog management, and seamless order taking-all from the palm of your hand. It also includes an integrated receipt printer for instant printed receipts.

• Manage Your Business: Use the device as a comprehensive business hub to manage item catalogs, track sales and inventory in real-time, generate detailed reports for simplified bookkeeping, and create staff profiles with customized access levels.

• Durable and Secure: Built with durability in mind, the Terminal features Corning® Gorilla® Glass 5 for extra protection, a barcode scanner, and AI-powered image recognition to quickly snap, scan, and add products.

“Small businesses need tools that are dependable, flexible and simple to use,” said Andrew Helms, CEO of SumUp USA. “The U.S. market demands solutions that offer both professional-grade power and the utmost flexibility, without the prohibitive cost and complexity of legacy systems. The SumUp Terminal brings payment acceptance and key business features together in a single device, making it easier for merchants to stay organized and serve customers wherever they are.”

SumUp is offering a 10% discount on the Terminal until November 23, 2025. This will be followed by a Black Friday/Cyber Monday promotion offering 25% off all readers from November 24, 2025, to December 1, 2025. For more information, click here.

About SumUp

SumUp is a global financial technology company driven by the mission of empowering small businesses all over the world. Established in 2012, SumUp is the financial partner for more than 4 million entrepreneurs in over 35 markets worldwide. In the United States, SumUp offers an ecosystem of affordable, easy-to-use financial products, such as point-of-sale and loyalty solutions, card readers, and invoicing.

For more information, please visit https://www.sumup.com

SOURCE: SumUp

View the original press release on ACCESS Newswire

University of Louisville Health pilots tool to tackle capacity constraints and improve patient flow across its system

PITTSBURGH, PA / ACCESS Newswire / November 20, 2025 / TeleTracking Technologies, the market leader in healthcare operations platforms for hospitals and health systems, today announced the launch of Decision IQ, the first AI-driven solution designed to manage patient flow at scale, during its annual TeleSummit customer conference in Nashville. The solution is already in place at University of Louisville Health (UofL Health), where leaders are using it to address capacity constraints and improve access.

Hospitals have long struggled to manage patient throughput – balancing incoming demand with limited space, staff, and resources – while relying on retrospective data that only shows what has already happened. Decision IQ replaces that model with proactive, system-wide visibility that empowers users to plan ahead and act in real time. At its core, Decision IQ is an AI-driven computational twin that unifies data from every department and ancillary service, creating a dynamic, system-wide view of patient movement. The technology simulates discharge priorities, predicts capacity needs, and translates those insights into clear direction within existing workflows to help care teams anticipate challenges before they escalate and reduce manual coordination so clinicians can focus more on patients.

“Decision IQ is about taking throughput data and making it actionable,” said Christopher Johnson, Co-CEO, TeleTracking. “By surfacing potential issues before they arise and recommending adjustments across the system, leaders gain the foresight to mitigate bottlenecks in advance – ensuring patients remain at the center of operational decisions. This marks a true transformation in how hospitals manage operations in the age of AI.”

UofL Health decided to implement Decision IQ after confronting growing capacity pressures and their impact on patient safety and care. As an early adopter, UofL saw the opportunity to apply AI to one of healthcare’s most persistent challenges – patient flow – and expand its longstanding partnership with TeleTracking beyond transfer operations.

“Our teams work tirelessly to move patients safely and efficiently, but traditional processes made it difficult to stay ahead of daily demand,” said Deanna Parker, MBA, MHA, BSN, RN, VP, Chief Nurse Executive, Downtown UofL Health. “Decision IQ gives us a forward-looking view of our operations, helping us anticipate where throughput challenges will occur and coordinate across departments before they impact patient care.”

About TeleTracking

TeleTracking is a technology company and the global leader in healthcare Operations Platforms, helping hospitals and health systems optimize patient flow, capacity, staffing workflows, and performance across clinical and operational domains. With over 35 years of experience, TeleTracking combines domain expertise with operational solutions that seamlessly integrate with EMRs and other enterprise systems, extending operational visibility across entire networks. Learn more at teletracking.com.

Media Contact:
Karina Stabile
Aria Marketing for TeleTracking
kstabile@ariamarketing.com
(516) 317-5835

SOURCE: TeleTracking

View the original press release on ACCESS Newswire

The acclaimed television series will highlight how LegalEASE is setting a new standard in legal benefits through innovation, education, and a national network of top-tier attorneys.

HOUSTON, TEXAS / ACCESS Newswire / November 20, 2025 / LegalEASE, a leading provider of legal insurance benefits for employers and organizations across the United States, will be featured on an upcoming episode of “Trending Today,” airing on Fox Business on November 23rd at 5:30 pm est. LegalEASE will also be spotlighted on the Trending Today Podcast, giving viewers and listeners an inside look at how the company is modernizing legal benefits and making high-quality legal support more accessible than ever.

“Trending Today” explores innovation across technology, health and wellness, consumer products, and business services-featuring companies that are elevating industries and transforming lives. LegalEASE stands out for its mission-driven approach: providing indispensable legal protection and education to employees at companies of all sizes.

With more than 50 years of experience and a nationwide network of credentialed attorneys, LegalEASE offers benefit plans that help employees navigate life’s biggest challenges-from real estate transactions and family law to identity theft protection, estate planning, financial disputes, and more. Their personalized matching system, hands-on guidance, and robust support tools make it easier for individuals to understand their options with confidence.

At the helm of LegalEASE is Bob Heston, the company’s CEO and the driving force behind its innovation. A recognized pioneer in the legal benefits industry, Heston has spent decades redefining how individuals access and understand legal support. His visionary approach, centered on education, empowerment, and exceptional service, has shaped LegalEASE into one of the most respected legal benefits providers in the country. Under his leadership, the company continues to expand its network, elevate service standards, and introduce groundbreaking solutions that simplify the legal process for employees and their families.

“At Trending Today, we highlight companies that empower people to live better, more secure lives,” said Liz Plummer, executive producer of Trending Today. “LegalEASE impressed our team with its commitment to education, personalized legal support, and its innovative approach to connecting employees with vetted attorneys. Their story represents the type of forward-thinking service that’s transforming the modern benefits landscape.”

 Viewers will learn how LegalEASE is taking the confusion and intimidation out of hiring legal help by offering easy onboarding, expert guidance, and curated legal resources. Through its Legal Access Plans and nationwide attorney networks, the company delivers a seamless experience that saves employees time, money, and stress-especially during life’s most difficult moments. Whether individuals are buying a home, starting a family, facing disputes, or navigating the unexpected, LegalEASE supports them with clarity and care.

“Our goal is simple: make legal protection a practical, accessible resource for every employee,” said Jason Weekley for LegalEASE. “We believe that legal benefits should offer more than coverage-they should offer guidance, reassurance, and a trusted path forward. Being featured on Trending Today allows us to share how we’re reshaping the way people access legal services.”

For more than 13 years, “Trending Today” has showcased industry leaders and innovators across technology, consumer products, luxury lifestyles, and business services. The award-winning series continues to shine a spotlight on organizations that are pushing boundaries and redefining what’s possible.

About ‘Trending Today’
Trending Today, the acclaimed television series airing on A&E, Bloomberg, and Fox Business, captures the entrepreneurial ambition that drives innovation around the world. Each episode highlights the latest technologies, market trends, and groundbreaking ideas through a thoughtfully curated lineup of inventors, innovators, and thought leaders. Spanning industries such as consumer products, luxury lifestyles, health, and technology, Trending Today features companies and leaders who are pushing boundaries and redefining excellence. To learn more, visit www.trendingtoday.com.

About LegalEASE
LegalEASE, a trusted leader in legal benefits for more than 50 years, provides organizations and their employees with comprehensive legal protection through expertly designed Legal Access Plans. With a nationwide network of credentialed attorneys and a proprietary matching system, LegalEASE connects individuals with the right legal experts for matters ranging from real estate and family law to identity theft, estate planning, financial disputes, and more. The company is dedicated to making legal support accessible, affordable, and easy to understand through personalized guidance, educational tools, and hands-on service. LegalEASE empowers employees to navigate life’s most important moments with confidence and clarity. To learn more, visit www.legaleaseplan.com.

Media Contacts:
Jason Weekley
jason_weekley@legaleaseplan.com

 Liz Plummer
Liz@trendingtoday.com

SOURCE: Trending Today

View the original press release on ACCESS Newswire

Crofelemer can potentially extend lives of MVID patients – infants and children who face the lethal natural history of the disease

Parenteral support reduction of up to 37% is groundbreaking; No approved treatments exist for MVID in any region

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 20, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, in support of a possible expedited approval pathway for crofelemer for treatment of intestinal failure in patients with the ultrarare genetic disorder microvillus inclusion disease (MVID), the company has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for the company’s ongoing placebo-controlled clinical trial of crofelemer in pediatric MVID patients.

MVID patients are born without the ability to absorb the basic nutrients of life, and are therefore subject to a lethal natural history and a lifetime of parenteral support which is associated with toxicities and comorbidities. The ability of crofelemer to decrease the volume of parenteral support is potentially life extending for these patients and is thus disease progression modifying. Crofelemer provides an opportunity for improved quality of life, potentially reducing the time MVID patients spend on parenteral nutrition and/or supplemental intravenous fluids by up to 37% a day from what is often up to 20 hours a day, 7 days a week to support the daily electrolyte and nutrient needs of the patient.

“In light of the initial groundbreaking results of the investigator-initiated trial (IIT) of crofelemer in the United Arab Emirates for treatment of MVID and in support of our efforts to make crofelemer available to children with MVID as quickly and efficiently as possible, as announced, the company met with the FDA on October 2, 2025 to seek their advice regarding our ongoing clinical trial of crofelemer for MVID treatment. Based on the feedback from the FDA during this meeting, we have proposed an amendment to our protocol for this study and submitted the amended protocol to the FDA for their review. Our expectation is that the amended protocol, along with the results of this study, if positive, will support a faster FDA review and approval of crofelemer for MVID,” said Pravin Chaturvedi, PhD, Jaguar’s Chief Scientific Officer and Chair of the Jaguar and Napo Scientific Advisory Board.

Jaguar has also discussed the potential for approval of crofelemer for MVID with the European Medicines Agency, the EU’s equivalent of the FDA, based on a study in potentially a small number of patients given the burden of MVID. “That’s how unprecedented crofelemer’s mechanism of action and these results are in intestinal failure patients with MVID,” said Lisa Conte, Jaguar’s founder, president, and CEO. “MVID is a devastating ultrarare pediatric disorder, with an estimated worldwide prevalence of only 100-200 patients, so a trial of crofelemer in just a small number of MVID patients is expected to be statistically meaningful.”

As presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, the initial groundbreaking results of an ongoing and independent IIT of crofelemer in the UAE for treatment of pediatric intestinal failure, which includes patients with intestinal failure due to MVID and short bowel syndrome (SBS-IF), demonstrate disease progression modification through reduction of total parenteral support (PS) in pediatric intestinal failure patients that ranged from 12 to 37%. For the initial MVID patient who has completed treatment, PS needs were reduced by up to 27% at the highest dose over the initial 12-week treatment period and up to 37% during the extension period upon reinitiation of crofelemer treatment, and also showed reduced frequency of loose watery stools. This finding supports continued evaluation of crofelemer to reduce PS needs for pediatric MVID patients.

MVID causes intestinal failure, a situation where the patient’s intestines are unable to absorb the fluids, electrolytes and nutrients required to survive and thrive. Intestinal failure is a debilitating, morbid and lifelong condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute parenteral support (PS). Most intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for these patients, PS is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problems including infections, metabolic complications, liver and kidney function problems – as well as a risk of neurodevelopmental delay. These symptoms may emerge at any time in intestinal failure patients, and often become life-threatening.

In addition to supporting the IIT in the UAE and conducting the placebo-controlled clinical trial of crofelemer in pediatric MVID patients at sites in the U.S., E.U., and Middle East, the company is also providing crofelemer powder for oral solution for use in two expanded access programs in the U.S. to treat intestinal failure in pediatric patients with MVID.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the amended protocol the company submitted to the FDA for the company’s ongoing trial of crofelemer for the treatment of intestinal failure in MVID patients will support a possible expedited approval pathway for crofelemer for this indication, Jaguar’s expectation that the ability of crofelemer to decrease the volume of PS is life extending and disease progression modifying for MVID patients, and that crofelemer provides an opportunity for improved quality of life for MVID patients by reducing the time MVID patients spend on parenteral nutrition and/or supplemental intravenous fluids by up to 37% a day, Jaguar’s expectation that the amended protocol, along with the results of the company’s study, if positive, will support a faster FDA review and approval of crofelemer for treatment of MVID, and Jaguar’s expectation that crofelemer could also be approved by the European Medicines Agency for MVID based on a study in potentially a small number of patients. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

NASHVILLE, TENNESSEE / ACCESS Newswire / November 20, 2025 / CenExel, a leading network of clinical research sites, is hosting a two-day Good Clinical Practice (GCP) training initiative beginning today, November 20, 2025, at the Sheraton Grand Nashville. Nearly 80 attendees, including Principal Investigators, sub-Investigators, regulatory and quality professionals, and clinical operations leaders, have gathered to enhance their understanding of the core regulatory and ethical standards that underpin every CenExel trial.

The training is facilitated by Deb Autor, JD, Elvira Cawthon, BS, MS, EMT-P, and Thom Mezak, MBA, PMP of Healthcare Innovation Catalysts, experts with extensive experience in regulatory compliance, data integrity, and investigator oversight. “Clinical research is rapidly evolving, but the core fundamental principles of GCP are still critical,” said Deb, who is also a former FDA Deputy Commissioner. “By prioritizing this level of rigorous, hands-on training, CenExel is aiming to strengthen its future, elevating the quality of its trials and ensuring that every partner and patient can trust the work being done across the network.”

Over the next two days, participants will explore key GCP principles, including ALCOA+++ data integrity, ICH GCP guidelines, and FDA and IRB regulations governing investigator responsibilities. The agenda also includes deep dives into Principal Investigator oversight, protocol compliance, adverse event reporting, and documentation standards, all of which are critical to maintaining the highest quality and ethical standards in clinical research.

“At CenExel, we hold ourselves to the highest level of scientific and regulatory excellence,” said Ryan Brooks, CenExel’s Chief Executive Officer. “This training reinforces our shared responsibility to sponsors, CROs, and – most importantly – our patients, ensuring that every study we conduct meets the highest standards of data integrity and participant safety.”

Hollie DeSmet, Vice President of Regulatory & Quality Assurance at CenExel, also emphasized the importance of this endeavor by saying, “The Good Clinical Practice training underscores our unwavering commitment to regulatory compliance and quality assurance across the CenExel network. By investing in rigorous education for our investigators and operational teams, we reinforce the integrity of our research processes and safeguard the trust placed in us by sponsors and patients. This initiative ensures that every study we conduct adheres to the highest ethical and scientific standards, advancing our mission to deliver reliable data and improve patient outcomes.”

Building on this foundation, the GCP training reflects CenExel’s broader investment in staff development, operational consistency, and collaboration across its nationwide network of Centers of Excellence. By aligning investigators and quality professionals under a shared framework of compliance and best practices, CenExel strengthens its ability to deliver high-quality data and reliable results to its partners, supporting the company’s mission to accelerate the development of new treatments through precise execution, trustworthy data, and the highest ethical standards.

SOURCE: CenExel Research

View the original press release on ACCESS Newswire

Capital will fuel product development, hiring, and expansion into large-scale manufacturing

SAN FRANCISCO, CA / ACCESS Newswire / November 20, 2025 / Parallax Worlds, the company building hyper-realistic simulations to stress-test robots before deployment, today announced a $4 million seed round, bringing total pre-seed and seed funding to $4.9 million. The round was led by Pear VC, with participation from GS Futures, Kakao Ventures, and Lightscape Partners, alongside angels and groups including Gaingels, Nova Threshold, and Mana Ventures. Prior backers include Conviction (Embed), Unusual Ventures, Spacecadet Ventures (co-leads of the pre-seed), and Boost VC.

Modern factories and warehouses want to adopt robots to meet reshoring goals and close labor gaps, but getting from pilot to production is slow, expensive, and risky. Even simple automation projects can take a year and require extensive on-site testing to achieve the uptime and reliability that production lines demand. Parallax Worlds eliminates that bottleneck by letting robotics builders and operators exhaustively test, measure, and validate performance in a high-fidelity digital twin before any hardware touches the floor.

“Production-grade reliability is the gap between a great demo and a great deployment,” said Tanmay Agarwal, Co-founder & CEO, Parallax Worlds. “Factories can’t afford robots that fail even for seconds; they need reliable performance and defensible ROI. Parallax Worlds gives builders and operators a way to measure reliability upfront, compress on-site iteration, and move from pilot to production faster.”

Parallax Worlds’ vertically integrated platform turns simple video capture (e.g., an iPhone walkthrough) into an accurate, interactive 3D environment. Today, teams can generate fully navigable digital twins from video and run interactive simulations using real robot software. The platform is actively expanding to support cloud-scale execution of thousands of edge-case scenarios and to deliver automated reliability, cost, and ROI metrics tied to specific tasks and site conditions. It integrates with industry physics engines and tooling (e.g., NVIDIA Omniverse, Unreal, Unity) while adding the missing layers, including fast video-to-3D, robotics-specific behaviors, and AI-assisted scenario generation.

“Parallax is building the missing simulation layer that bridges robotics R&D and real-world deployment by virtualizing physical spaces to make testing and reliability scalable,” said Payam Banazadeh, Visiting Partner, Pear VC. “Their digital-twin platform turns simulation into a true reliability engine, transforming what used to take years of costly trial and error into weeks of virtual iteration. It’s the kind of foundational shift that will redefine how entire industries build and trust automation, and we’re proud to back the Parallax team as they make this vision a reality.”

The company is led by a founding team with deep roots in both advanced robotics and industrial automation. Agarwal trained in Stanford’s robotics community under Prof. Fei-Fei Li and Prof. Jiajun Wu, and has developed software for systems ranging from home robots to self-driving vehicles. Aumkar Renavikar, Co-Founder and CTO, studied robotics at UIUC and supported factory-floor automation initiatives at BMW and Michelin, grounding the company’s approach in real industrial requirements.

The company has signed multiple robotics companies across manufacturing, construction, and select consumer-service use cases, including Orangewood Labs (industrial robots for manufacturing), BotBuilt (robots for home construction), and Rainier Labs (mobile welding robots).

“Parallax lets us validate robot behavior against real factory conditions using our actual control software,” said Abhinav Das, CEO at Orangewood Labs. “Being able to iterate on perception, planning, and edge-case handling before hardware is deployed materially accelerates our development cycle.”

With the new round, the company will expand into large enterprise manufacturing, while continuing to grow within its robotics-builder customer base. Funds will be used for product R&D, hiring, and go-to-market.

Reshoring and American dynamism demand more automation, but today only the largest manufacturers can shoulder the cost and time of traditional deployment cycles. By shifting reliability testing into a realistic virtual environment, Parallax Worlds aims to democratize access to robotics, enabling more factories and warehouses to adopt automation with confidence.

To learn more about the platform and schedule a demo, visit https://www.parallaxworlds.com/.

###

ABOUT PARALLAX WORLDS:

Parallax Worlds provides hyper-realistic simulation software to stress-test robots before deployment. The company’s platform transforms everyday video into high-fidelity digital twins and runs cloud-scale simulations with robotics-specific behaviors and AI-generated scenarios, delivering reliability, safety, and ROI insights before hardware hits the factory floor. Parallax Worlds is headquartered in San Francisco. Learn more at parallaxworlds.com.

MEDIA CONTACT: Nina Pfister, MAG PR at nina@mooringadvisorygroup.com.

SOURCE: Parallax Worlds

View the original press release on ACCESS Newswire

FRISCO, TEXAS / ACCESS Newswire / November 20, 2025 / GameSquare Holdings, Inc. (“GameSquare” or the “Company”) a next-generation media, entertainment, technology and digital native treasury company, today announced it repurchased 1,120,606 shares of its common stock for $565,806, representing an average price of approximately $0.50 per share. Following this transaction, the Company has approximately $3.9 million remaining under its current authorization.

Consistent with its capital allocation priorities, GameSquare intends to continue to opportunistically repurchase its common stock. Since October 2025, the Company has repurchased a total of 1,953,730 shares of its common stock for $1,164,955, representing an average price of approximately $0.60 per share.

“GameSquare has never been in a stronger financial and operating position,” said Justin Kenna, CEO of GameSquare. “At current share prices, we see a compelling dislocation between our intrinsic value and market value, and we will continue to allocate capital to opportunistic repurchases where we believe it meaningfully enhances shareholder value. This buyback is a clear signal of that conviction and the strength of our business model.”

About GameSquare Holdings, Inc.
GameSquare (NASDAQ:GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan Esports, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. As a digital-native business, GameSquare provides brands with unparalleled access to world-class creators and talent, delivering authentic connections across gaming, esports, and youth culture. Complementing our operating strategy, GameSquare has developed an innovative treasury management program designed to generate yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.

To learn more, visit www.gamesquare.com.

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company’s future performance, returns generated by its business strategies, revenue, growth and profitability; and the Company’s ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company’s ability to grow its business and being able to execute on its business plans and strategies, the success of Company’s vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to support its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company’s annual meeting and corporate governance, its ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company’s portfolio across entertainment and media platforms, dependence on the Company’s key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company’s most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Corporate Contact
Lou Schwartz, President
Phone: (216) 464-6400
Email: ir@gamesquare.com

Investor Relations
Andrew Berger
Phone: (216) 464-6400
Email: ir@gamesquare.com

Media Relations
Chelsey Northern / The Untold
Phone: (254) 855-4028
Email: pr@gamesquare.com

SOURCE: GameSquare Holdings, Inc.

View the original press release on ACCESS Newswire

Leading Regina clinic recognized for delivering timely, accurate MRI services with a patient-first approach.

REGINA, SASKATCHEWAN / ACCESS Newswire / November 20, 2025 / Open Skies MRI, a trusted leader in advanced diagnostic imaging, has won the 2025 Consumer Choice Award in the Diagnostic Imaging Clinics category for Regina. For the past 7 years this recognition has underscored Open Skies MRI’s dedication to delivering timely, accurate imaging services in a patient-first environment that prioritizes comfort and confidence.

Since 2012, Open Skies MRI has provided residents across Regina and Saskatchewan with access to high-quality MRI scans supported by clear communication and fast results. Patients and referring physicians rely on the clinic’s combination of modern technology and compassionate care to guide important health decisions.

Expert Diagnostic Care Close to Home
Open Skies MRI was founded to address a simple but vital need: more timely access to diagnostic imaging for Saskatchewan residents. By offering private MRI services, the clinic gives patients an alternative to long wait times, helping them get answers sooner and start treatment without unnecessary delays.

“Receiving the Consumer Choice Award once again reflects the confidence that patients and physicians place in our team’s commitment to timely, accurate, and patient-focused diagnostic imaging,” said Cam Barrett, Chief Executive Officer at Prairie Skies Medical Imaging. “Our priority is to ensure every patient feels informed and supported throughout their experience with us.”

Fast, Comfortable, and Accurate
Patients choose Open Skies MRI not only for its advanced equipment but for the experience itself. The clinic ensures that each visit is as smooth and stress-free as possible through:

• Timely Appointments: Faster booking and results mean less waiting and worry.

• Clear, Precise Images: High-resolution scans help physicians make informed diagnoses.

• Patient Comfort: Friendly staff, clear explanations, and a welcoming environment help ease anxiety.

• Seamless Physician Collaboration: Detailed reports are sent promptly to referring doctors, ensuring continuity of care.

This commitment to service has made Open Skies MRI a trusted partner in the region’s healthcare system.

Putting Patients First
Every member of the Open Skies MRI team understands that diagnostic imaging can feel intimidating. That’s why they prioritize education and compassion at every step – answering questions thoroughly, explaining procedures in plain language, and ensuring patients know what to expect before, during, and after their scan.

The result is a diagnostic experience that feels supportive and reassuring rather than rushed or impersonal.

A Community Partner in Health
Locally owned and operated, Open Skies MRI is proud to play a vital role in Regina’s health landscape. The clinic has built strong relationships with the Saskatchewan Health Authority, local physicians, specialists, and patients, earning a reputation for quality care delivered with integrity and respect. This dedication has earned Open Skies MRI the Consumer Choice Award for seven consecutive years – a testament to their consistent focus on trusted results and patient satisfaction.

Word-of-mouth referrals and positive patient stories continue to drive the clinic’s growth and reinforce its mission: to make top-tier diagnostic imaging accessible to everyone who needs it.

Continuing to Raise the Standard
With this Consumer Choice Award, Open Skies MRI has continued investing in newest imaging technologies and expanded imaging capacity to meet growing demand.

For more information about Open Skies MRI or to schedule an appointment, CLICK HERE or visit www.openskies.ca.

About Consumer Choice Award
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category win this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026

Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene

Further improves 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year on path to targeted cash breakeven in 2028

CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced program and financial updates at its Analyst Day event. The updates include mRNA pipeline progress and a three-year plan for strategic growth.

“Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics,” said Stéphane Bancel, CEO of Moderna. “We plan to deliver up to 10 percent revenue growth in 2026 while continuing to reduce our R&D investments and diversify further into oncology. Our financial outlook remains strong, and we are focused on disciplined execution as we advance our pipeline and bring innovative mRNA medicines to patients around the world.”

Business Strategy & Commercial Growth Drivers

Over the near term, Moderna will continue to build a large seasonal vaccine franchise targeting at-risk populations and propelling the Company to 2028 cash breakeven. The Company expects to invest the cash generated from its marketed products, Spikevax®, mRESVIA® and mNEXSPIKE®-as well as from anticipated launches of influenza, flu/COVID combination and Norovirus vaccines-into its oncology and rare disease programs. Investments in late-stage oncology and rare disease programs set the stage for additional growth in 2027 and 2028, with early-stage pipeline investments expected to mature in 2029 and beyond.

Commercial growth drivers include geographic expansion and new product launches. In 2026, the Company expects growth from the annualized impact of long-term partnerships in the UK, Canada and Australia that enhance research and development (R&D) investment, support national security and defense, and provide revenue visibility through onshore manufacturing. The Company also expects continued strong uptake of mNEXSPIKE in the U.S. and its launch in other countries.

In 2027, Europe represents a significant market for respiratory virus vaccines, as a competitor COVID contract lapses and more product approvals are expected. New potential long-term partnerships in Latin America and Asia-Pacific, as well as entry into the flu vaccine market, also position the Company for further expansion.

In 2028, Moderna anticipates a first-to-market flu/COVID combination vaccine and continued momentum with a potential novel Norovirus vaccine, expanding its seasonal franchise to as many as six approved products.

The Company’s existing commercial infrastructure supports these seasonal vaccine growth drivers. A focused Moderna U.S. commercial team engages the same customers across the retail pharmacy, government and healthcare provider (IDN) channels, and teams supporting the UK, Canada and Australia partnerships are established. Additionally, Moderna’s EU commercial infrastructure is in place and targeted investments will be made as needed.

Global Production Network

Since 2022, Moderna has streamlined its production sites into a global manufacturing network ready for new launches and delivering products for multi-year strategic partnerships. The Company exited eight contract manufacturers, announced new drug product capabilities in the U.S., and added three Moderna-built and managed facilities in the UK, Canada and Australia. Increased volume, manufacturing efficiency and waste reduction across Moderna sites is expected to drive a projected 10% improvement in gross margins over the next three years.

In the U.S., Moderna’s facility in Norwood, Massachusetts, enables scalable, end-to-end production by incorporating automation, robotics and AI to increase cost efficiency and reduce waste. The addition of new fill/finish capabilities in 2027 will provide end-to-end control and flexibility with greater speed.

Three new global sites in Laval, Canada; Harwell, UK; and Clayton, Australia enable local access to mRNA medicines and drive revenue diversification. These manufacturing facilities position the Company to deliver cost-optimized growth with margins consistent with U.S. operations.

The Marlborough, Massachusetts, facility was purpose-built for Moderna’s individualized neoantigen therapy, intismeran. Designed for speed and scalability with advanced automation and robotics, the site began clinical batch supply in September 2025 and is on track for commercial launch as the Company methodically right-sizes the intismeran manufacturing process to improve turnaround time and reduce costs.

Pipeline Progress

Highlights from Moderna’s approved vaccines and prioritized portfolio include:

Seasonal Vaccines

• Spikevax (mRNA-1273, COVID-19 vaccine): Approved in 40 countries.

• mNEXSPIKE (mRNA-1283, COVID-19 vaccine): Approved in the U.S. and Canada. The Company has filed and is targeting 2026 approvals in Australia, the EU, Japan and Taiwan.

• mRESVIA (mRNA-1345, RSV vaccine): Approved in 40 countries for adults aged 60 and older, and in 31 of those countries for adults 18-59 at increased risk for RSV disease.

• mRNA-1010 (Seasonal Influenza vaccine): Moderna expects to complete submissions for approval of mRNA-1010 in the U.S., EU, Canada and Australia by January 2026.

• mRNA-1083 (Seasonal flu + COVID combination vaccine): The Company’s mRNA-1083 filing is under review with the European Medicines Agency (EMA).Moderna submitted for approval to Health Canada in 2025. The Company is awaiting further guidance from the U.S. FDA on refiling.

• mRNA-1403 (Norovirus vaccine): The ongoing Phase 3 study has not accrued sufficient cases and is enrolling a second Northern Hemisphere season (2025-2026) for additional case accruals, which will inform the timing of the Phase 3 readout. Moderna expects an interim analysis in 2026.

Oncology Therapeutics

• mRNA-4157 (Intismeran autogene): Advancing in collaboration with Merck, with eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma.

• mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic NSCLC.

Rare Disease Therapeutics

• mRNA-3705 (Methylmalonic Acidemia therapeutic): Selected for the U.S. FDA’s START program, with a registrational study expected to begin in 2026.

For more details on the data and programmatic updates shared during Moderna’s Analyst Day investor event today, please visit “Events and Presentations” in the Investors section of the Moderna website.

Programs Discontinued

Based on the Company’s strategic prioritization, four programs in its pipeline are discontinued:

• mRNA-1647: The Company is discontinuing its congenital Cytomegalovirus (CMV) clinical development program. Moderna will continue to evaluate mRNA-1647 in an ongoing Phase 2 trial of bone marrow transplant patients.

• mRNA-1608: The Company’s herpes simplex virus (HSV) clinical development program will not advance to Phase 3.

• mRNA-1468: The Company’s Varicella-Zoster virus (VZV) clinical development program will not advance to Phase 3.

• mRNA-3745: The Company’s Glycogen Storage Disease Type 1a (GSD1a) clinical development program will not advance to Phase 2.

Financial Updates

Moderna expects up to 10% revenue growth in 2026, driven by the annualized impact of its long-term partnerships with the UK, Canada and Australia and continued strong uptake of mNEXSPIKE in the U.S. and launches in other countries. In addition, the Company has multiple growth opportunities in 2027 and beyond.

The Company is reducing its 2026 and 2027 expected cash costs to approximately $4.2 billion and a range of $3.5 to $3.9 billion, respectively. Moderna will achieve this through disciplined cost management and R&D prioritization, while manufacturing improvements are projected to improve gross margins by more than 10 percentage points over the next three years.

Moderna is increasing its R&D investment allocation in oncology and rare diseases as large infectious disease investments conclude. The Company’s balance sheet sufficiently funds its investments through targeted cash breakeven in 2028.

Today, Moderna announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds. The non-dilutive financing bolsters the Company’s strong balance sheet and provides increased flexibility. Moderna remains confident in its strong financial framework with enhanced liquidity and today updated its 2025 projected year-end cash and investment balance to a range of $7.1 to $7.6 billion, tied to the $0.6 billion initial loan draw and increased from previous expectations of $6.5 to $7.0 billion.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Spikevax®, mRESVIA® and mNEXSPIKE® are registered trademarks of Moderna.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s anticipated commercial growth drivers, including geographic expansion and new product launches; Moderna’s ability to achieve up to 10% revenue growth in 2026; Moderna’s ability to expand its seasonal vaccine franchise to up to six approved products by 2028; anticipated clinical readouts for Moderna’s oncology pipeline; Moderna’s 2026 and 2027 expected GAAP operating expenses; Moderna’s continued cost management and R&D prioritization and ability to reduce cash costs; Moderna’s balance sheet and targeted cash breakeven in 2028; Moderna’s 2025 projected year-end cash and investment balance; Moderna’s investments in its oncology and rare disease programs; additional growth in 2027-2028; anticipated strong update of mNEXSPIKE in 2026; Moderna’s global production network; the expectation that manufacturing improvements will improve gross margins over the next three years; anticipated regulatory filings and potential approvals; and anticipated milestones for Moderna’s pipeline programs. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

###

Moderna Contacts

Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire